| Budget Amount *help |
¥176,800,000 (Direct Cost: ¥136,000,000、Indirect Cost: ¥40,800,000)
Fiscal Year 2022: ¥34,710,000 (Direct Cost: ¥26,700,000、Indirect Cost: ¥8,010,000)
Fiscal Year 2021: ¥34,580,000 (Direct Cost: ¥26,600,000、Indirect Cost: ¥7,980,000)
Fiscal Year 2020: ¥34,580,000 (Direct Cost: ¥26,600,000、Indirect Cost: ¥7,980,000)
Fiscal Year 2019: ¥34,580,000 (Direct Cost: ¥26,600,000、Indirect Cost: ¥7,980,000)
Fiscal Year 2018: ¥38,350,000 (Direct Cost: ¥29,500,000、Indirect Cost: ¥8,850,000)
|
|---|
| Outline of Final Research Achievements |
The successful in vitro spermatogenesis in mice was achieved by supplementing the culture medium with AlbuMAX, a bovine serum albumin preparation. In this study, we elucidated the important constituents of AlbuMAX, with antioxidants and lysophospholipids being particularly crucial. Their combination resulted in an improved culture medium. Additionally, we created a small chip using polydimethylsiloxane, a material commonly used in microfluidic devices. By placing this chip over fragments of testicular tissue, we managed to enhance the efficiency of spermatogenesis. These combined efforts led us to achieve the world's first in vitro spermatogenesis in rats. Moreover, in a collaborative study with our team leader, Hayashi et al., we successfully induced the differentiation of functional Sertoli cells from mouse ES cells.
|
